Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $6.60.
A number of research firms have weighed in on CNTX. Piper Sandler increased their target price on shares of Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th. D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research report on Tuesday, March 24th. Wall Street Zen downgraded shares of Context Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a research report on Monday, April 20th. Finally, Guggenheim reissued a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a research report on Tuesday, March 24th.
Read Our Latest Report on Context Therapeutics
Context Therapeutics Price Performance
Context Therapeutics (NASDAQ:CNTX – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03. As a group, research analysts anticipate that Context Therapeutics will post -0.35 earnings per share for the current fiscal year.
Institutional Trading of Context Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CNTX. Vanguard Group Inc. increased its position in Context Therapeutics by 4.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock valued at $3,387,000 after purchasing an additional 134,449 shares during the period. Citadel Advisors LLC acquired a new stake in Context Therapeutics during the 3rd quarter valued at approximately $100,000. Blue Owl Capital Holdings LP increased its position in Context Therapeutics by 0.3% during the 4th quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock valued at $10,926,000 after purchasing an additional 25,000 shares during the period. Renaissance Technologies LLC grew its position in shares of Context Therapeutics by 58.8% during the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock worth $747,000 after buying an additional 188,202 shares during the period. Finally, State Street Corp grew its position in shares of Context Therapeutics by 8.5% during the 4th quarter. State Street Corp now owns 165,607 shares of the company’s stock worth $243,000 after buying an additional 13,000 shares during the period. Institutional investors and hedge funds own 14.03% of the company’s stock.
About Context Therapeutics
Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.
With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.
Featured Stories
- Five stocks we like better than Context Therapeutics
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
